BioLargo, Inc.
BLGO · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 45.4% | 107.9% | 132.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 44.2% | 50.3% | 48.6% | 43.6% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -22.8% | -34.2% | -86.6% | -264.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -13.5% | -28.7% | -76.4% | -291.5% |
| EPS Diluted | -0.008 | -0.012 | -0.017 | -0.03 |
| % Growth | 34.1% | 26.8% | 43.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |